Cryptococcosis

Organism & Virulence - Crypto's ID & Arsenal

• Organism: Cryptococcus neoformans (common, esp. AIDS) & C. gattii (tropics, immunocompetent/compromised).
  • Encapsulated yeast, 5-10 µm diameter.
  • Round to oval, reproduces by narrow-based budding.
  • Not dimorphic (yeast form only).
  • 
• Virulence Factors (Crypto's Arsenal):
  • Polysaccharide Capsule: Major! Mainly GXM (glucuronoxylomannan).
    • Antiphagocytic, inhibits leukocyte migration, immunosuppressive.

    ⭐ The capsule is its primary virulence factor; visualized by India Ink (negative stain) as a clear halo.

  • Melanin Production: Via laccase.
    • Protects from oxidative stress & host enzymes; neurotropic. (📌 "MELANIN: Mighty & Mind-loving")
  • Phospholipase B: Host membrane damage, tissue invasion.
  • Urease: Produces $NH_3$, ↑pH, aids CNS invasion (BBB).
  • Thermotolerance: Grows at 37°C.

Epidemiology & Risk Factors - Who Gets Hit & How

• Distribution & Species:
  • C. neoformans: Ubiquitous worldwide.
  • C. gattii: Predominantly tropical/subtropical; emerging temperate (Pacific NW).
• Reservoirs:
  • C. neoformans: Soil enriched with pigeon guano.
  • C. gattii: Eucalyptus trees, decaying wood.
• Transmission: Inhalation of airborne yeast/basidiospores. No human-to-human spread.
• Risk Factors (C. neoformans):
  • Cellular Immunodeficiency (Major):
    • HIV/AIDS: CD4+ T-cell count < 100 cells/µL (most critical). 📌 AIDS-defining illness.
    • Solid organ transplant recipients (on immunosuppressive therapy).
    • Prolonged high-dose corticosteroid therapy.
    • Hematologic malignancies (e.g., lymphoma, CLL).
    • Sarcoidosis.
    • Biologic agents (e.g., TNF-α inhibitors).
  • C. gattii: Notably can infect immunocompetent individuals, unlike typical C. neoformans.

⭐ Globally, cryptococcal meningitis is a leading opportunistic infection and a major cause of mortality in patients with advanced HIV/AIDS.

Clinical Manifestations - Brain & Lung Invasion

• Pulmonary Cryptococcosis:

  • Often asymptomatic in immunocompetent individuals.
  • Symptoms: Cough (productive or non-productive), low-grade fever, pleuritic chest pain, dyspnea, weight loss.
  • Radiology: Nodules (cryptococcomas), infiltrates (diffuse or lobar), pleural effusions, hilar lymphadenopathy.
  • Can disseminate, especially in immunocompromised.

• Cryptococcal Meningoencephalitis (CM): Most common CNS manifestation.

  • Predominantly in immunocompromised (HIV/AIDS, CD4 < 100 cells/µL).
  • Symptoms: Headache (often severe, persistent), fever, altered mental status, lethargy, nausea, vomiting, neck stiffness, photophobia, seizures.
  • Cranial nerve palsies (esp. VI, VII, VIII) common.
  • ↑ Intracranial pressure (ICP) is a major cause of morbidity/mortality.

    ⭐ Raised ICP is a hallmark of cryptococcal meningitis and a poor prognostic indicator. Management often requires therapeutic lumbar punctures or shunting.

• Other sites of dissemination (less common): Skin (papules, pustules, ulcers resembling molluscum contagiosum), bone, prostate, eyes (choroidoretinitis).

Diagnosis & Management - Unmasking & Eradicating

• Diagnosis:
  • CSF analysis: ↑Protein, ↓Glucose, Lymphocytic pleocytosis.
  • India Ink: Encapsulated budding yeast (halos). Sensitivity ~50-80% in AIDS.
    • 
  • Cryptococcal Antigen (CrAg): Serum/CSF. Rapid, high Sensitivity & Specificity.

    ⭐ CrAg titers often correlate with fungal burden and can monitor therapeutic response.

  • Culture (SDA): Gold standard.
• Management:
  • Manage ↑Intracranial Pressure (ICP): Aggressive! Therapeutic Lumbar Punctures (if Opening Pressure >25 $cm H_2O$); shunts if refractory.
  • Antifungal Therapy (Phased for CNS disease):

-   Induction (HIV+ or severe CNS): Liposomal Ampho B (LAmB) **3-4** mg/kg/d IV + Flucytosine (5-FC) **100** mg/kg/d PO (div. doses) x ≥**2** wks.
-   Consolidation: Fluconazole **400-800** mg/d PO x **8** wks.
-   Maintenance: Fluconazole **200** mg/d PO x ≥**1** yr.
-   Immune Reconstitution Inflammatory Syndrome (IRIS): Paradoxical worsening on ART; manage with NSAIDs/steroids if severe.

High‑Yield Points - ⚡ Biggest Takeaways

• Cryptococcus neoformans: Encapsulated yeast from pigeon droppings; acquired by inhalation.
• Key virulence: Large polysaccharide capsule (visualized by India Ink, resists phagocytosis).
• High risk: HIV/AIDS patients (CD4 < 100 cells/µL), other immunocompromised states.
• Predominant disease: Meningoencephalitis; also causes pulmonary and cutaneous infections.
• Diagnosis: Cryptococcal antigen (CrAg) test (CSF/serum) is crucial; CSF India Ink for direct visualization.
• Treatment: Amphotericin B + Flucytosine for induction, followed by Fluconazole maintenance.